Literature DB >> 1958747

Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features.

G E Verhoef1, C De Wolf-Peeters, A Ferrant, S Deprez, P Meeus, M Stul, P Zacheé, J J Cassiman, H Van den Berghe, M A Boogaerts.   

Abstract

We report on 22 patients with myelodysplastic syndrome (MDS), all of whom showed striking marrow fibrosis. Variable blood counts, often with teardrop poikilocytosis and a leukoerythroblastic picture, were present at diagnosis. Visceral enlargement was detected in 17 patients with a distinct splenomegaly in seven cases. All cases demonstrated dysplasia in at least two cell lineages. No specific cytogenetic abnormality seems to characterize this group of patients. Southern blot analysis showed no breakpoint cluster region rearrangement as observed in classical chronic myeloid leukemia. Ferrokinetic studies revealed quantitatively deficient erythropoiesis in all except two cases and an abnormally high fraction of ineffective erythropoiesis in all. Splenic erythropoiesis was present in eight patients. The median survival was 18 months. At the time of this report, 12 patients had died. The causes of death were disease progression (7 patients) and infection (5 patients). One might speculate that the present series of cases represents a transition between MDS and myeloproliferative disease, thereby displaying characteristics of both groups of diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1958747     DOI: 10.1007/bf01698371

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  48 in total

Review 1.  Cytogenetic and molecular studies of the Philadelphia translocation in myelodysplastic syndromes. Report of two cases and review of the literature.

Authors:  G Verhoef; P Meeus; M Stul; C Mecucci; J J Cassiman; H Van Den Berghe; M Boogaerts
Journal:  Cancer Genet Cytogenet       Date:  1992-04

2.  Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a.

Authors:  C W White; H M Sondheimer; E C Crouch; H Wilson; L L Fan
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

3.  A chromosomal profile of polycythemia vera.

Authors:  G Rege-Cambrin; C Mecucci; G Tricot; J L Michaux; A Louwagie; W Van Hove; H Francart; H Van den Berghe
Journal:  Cancer Genet Cytogenet       Date:  1987-04

4.  Hematologic manifestations associated with deletions of the long arm of chromosome 20.

Authors:  M P Davis; G W Dewald; R V Pierre; H C Hoagland
Journal:  Cancer Genet Cytogenet       Date:  1984-05

5.  Assessment of bone marrow and splenic erythropoiesis in myelofibrosis.

Authors:  A Ferrant; J Rodhain; F Cauwe; M Cogneau; C Beckers; J L Michaux; R Verwilghen; G Sokal
Journal:  Scand J Haematol       Date:  1982-11

6.  Purification and properties of an endothelial cell growth factor from human platelets.

Authors:  K Miyazono; T Okabe; A Urabe; F Takaku; C H Heldin
Journal:  J Biol Chem       Date:  1987-03-25       Impact factor: 5.157

Review 7.  Acute ("malignant") myelosclerosis.

Authors:  R M Bearman; G A Pangalis; H Rappaport
Journal:  Cancer       Date:  1979-01       Impact factor: 6.860

8.  Cellular transformation by coordinated action of three peptide growth factors from human platelets.

Authors:  R K Assoian; G R Grotendorst; D M Miller; M B Sporn
Journal:  Nature       Date:  1984 Jun 28-Jul 4       Impact factor: 49.962

Review 9.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

10.  Megakaryoblastic leukemia presenting as acute myelofibrosis -- a study of four cases with the platelet-peroxidase reaction.

Authors:  B J Bain; D Catovsky; M O'Brien; H G Prentice; E Lawlor; T O Kumaran; S R McCann; E Matutes; D A Galton
Journal:  Blood       Date:  1981-08       Impact factor: 22.113

View more
  12 in total

1.  Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.

Authors:  Nicolaus Kröger; Tatjana Zabelina; Anja van Biezen; Ronald Brand; Dietger Niederwieser; Rodrigo Martino; Zi Yi Lim; Francesco Onida; Christoph Schmid; Laurent Garderet; Marie Robin; Michael van Gelder; Reinhard Marks; Argiris Symeonidis; Guido Kobbe; Theo de Witte
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

Authors:  Bin Fu; Chi Young Ok; Maitrayee Goswami; Wei Xei; Jesse M Jaso; Tariq Muzzafar; Carlos Bueso-Ramos; Srdan Verstovsek; Guillermo Garcia-Manero; L Jeffrey Medeiros; Sa A Wang
Journal:  Ann Hematol       Date:  2013-05-10       Impact factor: 3.673

3.  Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.

Authors:  Hemant Sarin
Journal:  Mol Clin Oncol       Date:  2015-12-16

4.  TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.

Authors:  Sanam Loghavi; Alyaa Al-Ibraheemi; Zhuang Zuo; Guillermo Garcia-Manero; Mariko Yabe; Sa A Wang; Hagop M Kantarjian; Cameron C Yin; Roberto N Miranda; Raja Luthra; L Jeffrey Medeiros; Carlos E Bueso-Ramos; Joseph D Khoury
Journal:  Br J Haematol       Date:  2015-06-30       Impact factor: 6.998

5.  Patients of Myelodysplastic Syndrome with Mild/Moderate Myelofibrosis and a Monosomal Karyotype are Independently Associated with an Adverse Prognosis: Long-Term Follow-Up Data.

Authors:  Na Wang; Hongzhi Xu; Qing Li; Xiaosheng Fang; Jie Liu; Xiaohui Sui; Lingyan Zhang; Yujie Jiang; Xin Wang
Journal:  Cancer Manag Res       Date:  2020-07-16       Impact factor: 3.989

6.  Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance.

Authors:  D Marisavljević; Z Rolović; V Cemerikić; D Bosković; M Colović
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

7.  Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.

Authors:  G Lambertenghi-Deliliers; C Annaloro; A Oriani; D Soligo; E Pozzoli; E E Polli
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

Review 8.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

9.  Myelodysplastic syndrome with myelofibrosis transformed to a precursor B-cell acute lymphoblastic leukemia: a case report with review of the literature.

Authors:  Ayed A Algarni; Mojtaba Akhtari; Kai Fu
Journal:  Case Rep Hematol       Date:  2012-03-29

10.  Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis.

Authors:  Shuichiro Takahashi; Riko Tsumanuma; Keiko Aizawa; Mitsumasa Osakabe; Kunihiko Maeda; Ejiro Omoto
Journal:  Intern Med       Date:  2016-11-15       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.